Does the media refer more to TWST or DNA?

In the previous week, Twist Bioscience had 8 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 11 mentions for Twist Bioscience and 3 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 1.61 beat Ginkgo Bioworks' score of -0.17 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 10 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DNA or FTRE more profitable?

Fortrea has a net margin of -3.18% compared to Ginkgo Bioworks' net margin of -259.96%. Fortrea's return on equity of 10.72% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -259.96% -60.27% -26.88% Fortrea -3.18% 10.72% 2.17%

Does the media prefer DNA or FTRE?

In the previous week, Fortrea had 9 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 12 mentions for Fortrea and 3 mentions for Ginkgo Bioworks. Fortrea's average media sentiment score of 0.42 beat Ginkgo Bioworks' score of -0.17 indicating that Fortrea is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Fortrea 3 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DNA or PSNL more profitable?

Personalis has a net margin of -153.84% compared to Ginkgo Bioworks' net margin of -259.96%. Personalis' return on equity of -46.47% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -259.96% -60.27% -26.88% Personalis -153.84% -46.47% -35.30%

Does the media prefer DNA or PSNL?

In the previous week, Personalis had 2 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 5 mentions for Personalis and 3 mentions for Ginkgo Bioworks. Personalis' average media sentiment score of 0.94 beat Ginkgo Bioworks' score of -0.17 indicating that Personalis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Personalis 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BLFS or DNA?

In the previous week, Ginkgo Bioworks had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 3 mentions for Ginkgo Bioworks and 2 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.00 beat Ginkgo Bioworks' score of -0.17 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, AZTA or DNA?

Azenta has higher revenue and earnings than Ginkgo Bioworks. Azenta is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Azenta $593.82M 2.31 -$55.76M -$2.76 N/A Ginkgo Bioworks $170.15M 2.75 -$312.76M -$5.01 N/A

Is AZTA or DNA more profitable?

Azenta has a net margin of -20.63% compared to Ginkgo Bioworks' net margin of -259.96%. Azenta's return on equity of 1.18% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Azenta -20.63% 1.18% 0.97% Ginkgo Bioworks -259.96% -60.27% -26.88%

Does the media favor AZTA or DNA?

In the previous week, Azenta had 8 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 11 mentions for Azenta and 3 mentions for Ginkgo Bioworks. Azenta's average media sentiment score of 1.18 beat Ginkgo Bioworks' score of -0.17 indicating that Azenta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Azenta 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Ginkgo Bioworks (DNA) Competitors

$6.95 0.00 (0.00%)

As of 03:58 PM Eastern

Compare

DNA vs. TWST, FTRE, PSNL, BLFS, and AZTA

Should you buy Ginkgo Bioworks stock or one of its competitors? Ginkgo Bioworks's main competitors and comparable companies include Twist Bioscience (TWST), Fortrea (FTRE), Personalis (PSNL), BioLife Solutions (BLFS), and Azenta (AZTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Ginkgo Bioworks compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Ginkgo Bioworks (NYSE:DNA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Twist Bioscience presently has a consensus price target of $98.30, suggesting a potential downside of 21.18%. Ginkgo Bioworks has a consensus price target of $7.00, suggesting a potential upside of 0.72%. Given Ginkgo Bioworks' higher probable upside, analysts clearly believe Ginkgo Bioworks is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Twist Bioscience had 8 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 11 mentions for Twist Bioscience and 3 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 1.61 beat Ginkgo Bioworks' score of -0.17 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	10 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ginkgo Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Twist Bioscience has a net margin of -31.66% compared to Ginkgo Bioworks' net margin of -259.96%. Twist Bioscience's return on equity of -28.64% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	20.77	-$77.67M	-$2.22	N/A
Ginkgo Bioworks	$170.15M	2.75	-$312.76M	-$5.01	N/A

Twist Bioscience has a beta of 2.22, suggesting that its share price is 122% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

78.6% of Ginkgo Bioworks shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Twist Bioscience beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Fortrea?

Ginkgo Bioworks (NYSE:DNA) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Fortrea has a net margin of -3.18% compared to Ginkgo Bioworks' net margin of -259.96%. Fortrea's return on equity of 10.72% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Fortrea	-3.18%	10.72%	2.17%

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 0.7% of Fortrea shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ginkgo Bioworks presently has a consensus target price of $7.00, suggesting a potential upside of 0.72%. Fortrea has a consensus target price of $20.75, suggesting a potential upside of 17.23%. Given Fortrea's stronger consensus rating and higher probable upside, analysts clearly believe Fortrea is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Ginkgo Bioworks has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.97, suggesting that its stock price is 97% more volatile than the broader market.

Ginkgo Bioworks has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	2.75	-$312.76M	-$5.01	N/A
Fortrea	$2.72B	0.62	-$986.20M	-$0.91	N/A

In the previous week, Fortrea had 9 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 12 mentions for Fortrea and 3 mentions for Ginkgo Bioworks. Fortrea's average media sentiment score of 0.42 beat Ginkgo Bioworks' score of -0.17 indicating that Fortrea is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortrea	3 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fortrea beats Ginkgo Bioworks on 11 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Personalis?

Ginkgo Bioworks (NYSE:DNA) and Personalis (NASDAQ:PSNL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

Personalis has lower revenue, but higher earnings than Ginkgo Bioworks. Personalis is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	2.75	-$312.76M	-$5.01	N/A
Personalis	$69.65M	25.86	-$81.27M	-$1.09	N/A

Personalis has a net margin of -153.84% compared to Ginkgo Bioworks' net margin of -259.96%. Personalis' return on equity of -46.47% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Personalis	-153.84%	-46.47%	-35.30%

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 4.2% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ginkgo Bioworks currently has a consensus target price of $7.00, suggesting a potential upside of 0.72%. Personalis has a consensus target price of $14.54, suggesting a potential downside of 15.49%. Given Ginkgo Bioworks' higher possible upside, analysts plainly believe Ginkgo Bioworks is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Personalis	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Personalis had 2 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 5 mentions for Personalis and 3 mentions for Ginkgo Bioworks. Personalis' average media sentiment score of 0.94 beat Ginkgo Bioworks' score of -0.17 indicating that Personalis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Personalis	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ginkgo Bioworks has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Personalis has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market.

Summary

Personalis beats Ginkgo Bioworks on 10 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioLife Solutions has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

In the previous week, Ginkgo Bioworks had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 3 mentions for Ginkgo Bioworks and 2 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.00 beat Ginkgo Bioworks' score of -0.17 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ginkgo Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioLife Solutions currently has a consensus price target of $31.38, indicating a potential downside of 10.99%. Ginkgo Bioworks has a consensus price target of $7.00, indicating a potential upside of 0.72%. Given Ginkgo Bioworks' higher possible upside, analysts clearly believe Ginkgo Bioworks is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

BioLife Solutions has a net margin of 53.29% compared to Ginkgo Bioworks' net margin of -259.96%. BioLife Solutions' return on equity of 2.70% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

BioLife Solutions has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	17.90	-$4.59M	$1.16	30.39
Ginkgo Bioworks	$170.15M	2.75	-$312.76M	-$5.01	N/A

Summary

BioLife Solutions beats Ginkgo Bioworks on 13 of the 17 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Azenta?

Azenta (NASDAQ:AZTA) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Azenta had 8 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 11 mentions for Azenta and 3 mentions for Ginkgo Bioworks. Azenta's average media sentiment score of 1.18 beat Ginkgo Bioworks' score of -0.17 indicating that Azenta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Azenta	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Azenta shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 10.9% of Azenta shares are owned by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Azenta has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

Azenta currently has a consensus target price of $41.20, suggesting a potential upside of 31.50%. Ginkgo Bioworks has a consensus target price of $7.00, suggesting a potential upside of 0.72%. Given Azenta's stronger consensus rating and higher possible upside, equities research analysts plainly believe Azenta is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Azenta has a net margin of -20.63% compared to Ginkgo Bioworks' net margin of -259.96%. Azenta's return on equity of 1.18% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Azenta	-20.63%	1.18%	0.97%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

Azenta has higher revenue and earnings than Ginkgo Bioworks. Azenta is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Azenta	$593.82M	2.31	-$55.76M	-$2.76	N/A
Ginkgo Bioworks	$170.15M	2.75	-$312.76M	-$5.01	N/A

Summary

Azenta beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

Get Ginkgo Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNA vs. The Competition

Export

Metric	Ginkgo Bioworks	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$468.01M	$9.93B	$7.17B	$23.48B
Dividend Yield	N/A	1.46%	2.53%	3.73%
P/E Ratio	-1.39	65.01	272.99	29.41
Price / Sales	2.75	112.23	612.35	19.75
Price / Cash	N/A	26.86	77.82	32.15
Price / Book	1.11	35.98	12.85	7.60
Net Income	-$312.76M	$56.67B	$3.47B	$1.07B
7 Day Performance	-0.43%	-0.83%	1.25%	-0.07%
1 Month Performance	-25.87%	4.54%	5.81%	-0.42%
1 Year Performance	-40.39%	26.48%	25.76%	13.25%

Ginkgo Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNA Ginkgo Bioworks	1.1939 of 5 stars	$6.95 flat	$7.00 +0.7%	-38.9%	$468.01M	$170.15M	N/A	640	Analyst Forecast Gap Down
TWST Twist Bioscience	1.7086 of 5 stars	$139.00 -1.7%	$98.30 -29.3%	+395.0%	$8.87B	$376.57M	N/A	990	Positive News Gap Down
FTRE Fortrea	3.3799 of 5 stars	$18.37 -2.3%	$20.75 +13.0%	+74.2%	$1.79B	$2.72B	N/A	14,300
PSNL Personalis	1.902 of 5 stars	$16.78 -1.7%	$14.54 -13.4%	+247.0%	$1.79B	$69.65M	N/A	400
BLFS BioLife Solutions	2.2028 of 5 stars	$37.07 +1.9%	$31.38 -15.4%	+41.9%	$1.78B	$96.21M	31.96	440	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DNA) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, FTRE, PSNL, BLFS, and AZTA

How does Ginkgo Bioworks compare to Twist Bioscience?

Summary

How does Ginkgo Bioworks compare to Fortrea?

Summary

How does Ginkgo Bioworks compare to Personalis?

Summary

How does Ginkgo Bioworks compare to BioLife Solutions?

Summary

How does Ginkgo Bioworks compare to Azenta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, FTRE, PSNL, BLFS, and AZTA

How does Ginkgo Bioworks compare to Twist Bioscience?

Do analysts rate TWST or DNA?

Does the media refer more to TWST or DNA?

Is TWST or DNA more profitable?

Which has stronger valuation and earnings, TWST or DNA?

Which has more risk & volatility, TWST or DNA?

Do institutionals & insiders have more ownership in TWST or DNA?

Summary

How does Ginkgo Bioworks compare to Fortrea?

Is DNA or FTRE more profitable?

Do institutionals & insiders hold more shares of DNA or FTRE?

Do analysts rate DNA or FTRE?

Which has more volatility and risk, DNA or FTRE?

Which has higher valuation & earnings, DNA or FTRE?

Does the media prefer DNA or FTRE?

Summary

How does Ginkgo Bioworks compare to Personalis?

Which has preferable valuation & earnings, DNA or PSNL?

Is DNA or PSNL more profitable?

Do insiders and institutionals have more ownership in DNA or PSNL?

Do analysts prefer DNA or PSNL?

Does the media prefer DNA or PSNL?

Which has more risk & volatility, DNA or PSNL?

Summary

How does Ginkgo Bioworks compare to BioLife Solutions?

Do institutionals and insiders believe in BLFS or DNA?

Which has more risk and volatility, BLFS or DNA?

Does the media favor BLFS or DNA?

Do analysts rate BLFS or DNA?

Is BLFS or DNA more profitable?

Which has stronger earnings & valuation, BLFS or DNA?

Summary

How does Ginkgo Bioworks compare to Azenta?

Does the media favor AZTA or DNA?

Do institutionals and insiders hold more shares of AZTA or DNA?

Which has more volatility & risk, AZTA or DNA?

Do analysts rate AZTA or DNA?

Is AZTA or DNA more profitable?

Which has preferable valuation & earnings, AZTA or DNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools